Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2010-N-0555]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the 
                        **Federal Register**
                         concerning each proposed collection of 
                        ( print page 69448)
                        information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection requirements for the tracking of medical devices.
 DATES: Submit either electronic or written comments on the collection of information by January 11, 2011.
 ADDRESSES: Submit electronic comments on the collection of information to 
                        *http://www.regulations.gov.*
                         Submit written comments on the collection of information to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.
 FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, MD 20850, 301-796-5156, 
                        *Daniel.Gittleson@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. “Collection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the 
                    **Federal Register**
                     concerning each proposed collection of information, including each proposed extension of an existing collection of information before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. In preparing this notice, the agency reviewed a comment that was posted in response to the 60-day notice of February 5, 2008 (73 FR 6729) (Docket No. FDA-2008-N-0050). FDA transitioned to the Federal Dockets Management System (FDMS) in January 2008, and this comment was not posted to the docket until after the closing of the comment period. The comment responded to item 1 (whether the information collection is necessary) and item 3 (how to enhance quality of ICR). With regard to item 1, the comment emphasized the importance of medical device tracking and supported the information collection request in full. With regard to item 3, the comment said that implementing the unique device identification provision (UDI) of the Food and Drug Administration Modernization Act (FDAMA) would go a long way in enhancing medical device tracking, and the agency is currently undertaking this effort. Medical Devices; Device Tracking—21 CFR Part 821 (OMB Control Number 0910-0442)—Extension Section 211 of the Food and Drug Administration Modernization Act (FDAMA) (Pub. L. 105-115) became effective on February 19, 1998. FDAMA amended the previous medical device tracking provisions under section 519(e)(1) and (e)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360i(e)(1) and (e)(2)) and were added by the Safe Medical Devices Act of 1990 (SMDA) (Pub. L. 101-629). Unlike the tracking provisions under SMDA which required tracking of any medical device meeting certain criteria, FDAMA allows FDA discretion in applying tracking provisions to medical devices meeting certain criteria, and provides that tracking requirements for medical devices can be imposed only after FDA issues an order. In the 
                    **Federal Register**
                     of February 8, 2002 (67 FR 5943), FDA issued a final rule which conformed existing tracking regulations to changes in tracking provisions effected by FDAMA under part 821 (21 CFR part 821). Section 519(e)(1) of the act, as amended by FDAMA, provides that FDA may require by order, that a manufacturer adopt a method for tracking a class II or III medical device, if the device meets one of the three following criteria: (1) The failure of the device would be reasonably likely to have serious adverse health consequences, (2) the device is intended to be implanted in the human body for more than 1 year (referred to as a “tracked implant”), or (3) the device is life-sustaining or life-supporting (referred to as a “tracked l/s-l/s device”) and is used outside a device user facility. Tracked device information is collected to facilitate identifying the current location of medical devices and patients possessing those devices, to the extent that patients permit the collection of identifying information. Manufacturers and FDA (where necessary), use the data to: (1) Expedite the recall of distributed medical devices that are dangerous or defective and (2) facilitate the timely notification of patients or licensed practitioners of the risks associated with the medical device. In addition, the regulations include provisions for: (1) Exemptions and variances; (2) system and content requirements for tracking; (3) obligations of persons other than device manufacturers, e.g., distributors; records and inspection requirements; (4) confidentiality; and (5) record retention requirements. Respondents for this collection of information are medical device manufacturers, importers, and distributors of tracked implants or tracked l/s-l/s devices used outside a device user facility. Distributors include multiple and final distributors, including hospitals. FDA estimates the burden of this collection of information as follows: Table 1—Estimated Annual Reporting Burden1
CFR section
Number of 
                             respondents
Annual 
                             frequency per  
                             response
Total annual responses
Hours per 
                             response
Total hours821.1(d)
1
1
1
1
1821.2 and 821.30(e)
1
1
1
1
1821.25(a)
12
1
12
76
912( print page 69449)821.25(d)
1
1
1
1
1Total




9151
                         There are no capital costs or operating and maintenance costs associated with this collection of information.
 Table 2—Estimated Annual Recordkeeping Burden1
CFR section
Number of 
                             recordkeepers
Annual 
                             frequency of  
                             recordkeeping
Total annual records
Hours per record
Total hours821.25(b)
12
46,260
555,120
1
555,120821.25(c)2
12
1
12
63
756821.25(c)(3)
12
1,124
13,488
1
13,488Total




569,3641
                         There are no capital costs or operating and maintenance costs associated with this collection of information.2
                         One time burden.
 Table 3—Estimated Annual Third-Party Disclosure Burden1
21 CFR section
Number of 
                             respondents
Annual 
                             frequency of  
                             disclosure
Total annual 
                             disclosures
Hours per 
                             disclosure
Total hours821.30(a) and (b)
17,000
1
17,000
1
17,000821.30(c) and (d)
17,000
1
17,000
1
17,000Total Hours




34,0001
                         There are no capital costs or operating and maintenance costs associated with this collection of information.
 The annual hourly burden for respondents involved with medical device tracking is estimated to be 604,279 hours per year. The burden estimates cited in tables 1, 2, and 3 of this document are based on the number of device tracking orders issued in the last 3 years. This regulation also refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by Office of Management and Budget under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The collections of information found in 21 CFR 821.2(b), 821.25(e), and 821.30(e) have been approved under OMB control number 0910-0183. Dated: November 5, 2010. Leslie Kux, Acting Assistant Commissioner for Policy.


[FR Doc. 2010-28441 Filed 11-10-10; 8:45 am] BILLING CODE 4160-01-P